Clinical Research
Oral GLP-1 Clinical Trials: What the Research Shows
Oral semaglutide has demonstrated weight-loss benefits in large human clinical trials. This article reviews what the OASIS 1, OASIS 4, and PIONEER 4 trials actually measured — and why those results cannot automatically be applied to compounded oral GLP-1 medications, which are different products.
Educational content published by Surfbound Health. It is not medical advice and does not replace an individual evaluation by a licensed provider.
OASIS 1 & OASIS 4
Oral semaglutide in obesity
Up to 15.1% mean weight loss
In the OASIS 1 trial at 68 weeks
Formulation-specific
Results do not transfer to compounded products
The evidence in brief
In randomized, placebo-controlled human trials, oral semaglutide reduced body weight in adults with overweight or obesity — for example, 15.1% at 50 mg over 68 weeks (OASIS 1) and 13.6% at 25 mg over 64 weeks (OASIS 4), versus 2.4% and 2.2% for placebo. These results belong to the specific FDA-approved oral formulations and doses that were tested. They do not establish equivalent absorption, effectiveness, or safety for compounded oral GLP-1 medications, which are different products and are not FDA-approved.
- Oral semaglutide has demonstrated efficacy in human clinical trials.
- Those results are specific to the tested pharmaceutical formulations and doses.
- Compounded formulations are not automatically therapeutically equivalent.
- Compounded oral tirzepatide and oral semaglutide–tirzepatide combinations do not have comparable established human efficacy evidence.
- Patients should discuss treatment options with a licensed clinician.
The three trials in detail
Each trial below studied a specific, FDA-approved oral semaglutide formulation at a specific dose. The results are summarized from the peer-reviewed publications, with the study limitations kept next to the numbers.
OASIS 1
Oral semaglutide 50 mg in adults with overweight or obesity
- Formulation studied
- Oral semaglutide 50 mg, once daily
- Design
- Randomized, double-blind, placebo-controlled
- Population
- Adults with overweight or obesity without type 2 diabetes
- Duration
- 68 weeks
15.1% average body-weight reduction vs 2.4% for placebo
Participants taking oral semaglutide 50 mg experienced an average 15.1% reduction in body weight over 68 weeks, compared with 2.4% for placebo.
Study limitations and interpretation
- The trial studied one specific FDA-approved oral formulation at a specific 50 mg dose — a dose that is higher than approved oral semaglutide products and is not available as a compounded tablet.
- The results are group averages. Individual responses vary, and averages are not a prediction of any individual outcome.
- The findings describe the studied product, not compounded oral semaglutide, which is a different formulation that has not been studied in the same way.
OASIS 4
Oral semaglutide 25 mg in adults with overweight or obesity
- Formulation studied
- Oral semaglutide 25 mg, once daily
- Design
- Randomized, double-blind, placebo-controlled
- Population
- Adults with overweight or obesity
- Primary endpoint
- 64 weeks
13.6% average weight reduction vs 2.2% for placebo
In OASIS 4, oral semaglutide 25 mg produced an average 13.6% weight reduction at 64 weeks, compared with 2.2% for placebo.
Study limitations and interpretation
- The result is tied to the formulation and the 25 mg dose that were studied, not to compounded oral semaglutide products.
- As with OASIS 1, the figures are on-treatment averages from a specific trial population, not a per-person guarantee.
- No head-to-head trial compares a compounded oral semaglutide product against the studied formulation.
PIONEER 4
Oral semaglutide 14 mg in adults with type 2 diabetes
- Formulation studied
- Oral semaglutide 14 mg, once daily
- Comparators
- Injectable liraglutide and placebo
- Population
- Adults with type 2 diabetes
- Focus
- Glycemic control and body weight
Glycemic and weight outcomes in a type 2 diabetes population
PIONEER 4 compared oral semaglutide 14 mg with injectable liraglutide and placebo in adults with type 2 diabetes. It measured glycemic control (HbA1c) and body-weight outcomes in a population that differs from the obesity trials above.
Study limitations and interpretation
- The participants had type 2 diabetes, which is a different clinical population from the adults with overweight or obesity in the OASIS trials, so the weight outcomes are not directly transferable.
- The dose studied was 14 mg — a different dose from the OASIS trials and from most compounded products.
- This trial studied an FDA-approved oral formulation; it is not direct evidence of the safety or efficacy of any compounded oral product.
Why oral formulation matters
Semaglutide is a peptide. Peptides are normally broken down in the stomach and gut and are poorly absorbed intact through the intestinal wall. For an oral peptide medication to work, the formulation has to overcome that barrier — which is why oral peptide drugs are engineered products, not simply the injectable drug placed in a tablet.
The FDA-approved oral semaglutide product studied in the trials above pairs semaglutide with an absorption enhancer called SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate), and it must be taken in a specific way — on an empty stomach, with a limited amount of water, followed by a waiting period before eating or drinking. That formulation and those administration rules are part of what was tested in the clinical trials.
Absorption is formulation- and administration-dependent
Because oral peptide absorption depends on the specific formulation and how it is taken, it should not be assumed that every compounded oral semaglutide product absorbs the same way, or to the same degree, as the FDA-approved product that was studied. A compounded oral formulation is a different product and is not FDA-approved.
Primary sources: Rybelsus (oral semaglutide) U.S. Prescribing Information and FDA — Compounding and the FDA: Questions and Answers.
What the evidence does not establish
The single most important distinction on this page is between the products that were studied and the compounded products that are actually sold. They are not interchangeable on the basis of the trial data.
1. FDA-approved oral semaglutide formulations
The trials above provide evidence for specific FDA-approved oral semaglutide formulations at the doses studied. This is the strongest evidence on this page.
2. Surfbound's compounded oral semaglutide formulation
The compounded oral semaglutide that Surfbound offers is a different, non-FDA-approved formulation. The trial results above are not evidence of its absorption, effectiveness, or safety.
3. Compounded oral tirzepatide
There is no FDA-approved oral tirzepatide, and no large randomized human trial establishes weight-loss efficacy for a compounded oral tirzepatide product. Injectable tirzepatide trials do not demonstrate efficacy for an oral compounded version.
4. Compounded oral semaglutide plus tirzepatide
No human trial establishes that combining semaglutide and tirzepatide in one oral product produces better results. Using both active ingredients together has not been shown to improve outcomes without direct clinical evidence.
In plain terms: evidence for an injectable or a compounded product of one type does not transfer to a compounded product of another type. Claims that a compounded oral product is "the same" as a studied formulation are not supported by the clinical evidence.
What should patients look for in an oral GLP-1 provider?
A practical checklist for evaluating any oral GLP-1 telehealth provider — including Surfbound. It is meant to be used, not just read.
Clear identification of the formulation
The provider should state which product is prescribed and whether it is an FDA-approved product or a compounded one.
Transparent billing and ongoing costs
You should be able to see the full recurring cost — medication, provider review, shipping, and any membership or consultation fees — before you pay.
An independent licensed clinical evaluation
A licensed provider should review your health history and decide medical appropriateness. A questionnaire alone is not an evaluation.
Identification of the dispensing pharmacy
You should be able to find out which licensed pharmacy prepares and dispenses the medication.
Appropriate follow-up support
There should be a clear way to reach a provider or support team with questions after you start treatment.
A clear explanation of uncertainties and risks
The provider should explain what is known, what is not established for the specific product, and what side effects or risks to watch for.
A legitimate prescription and fulfillment process
Treatment should be dispensed by a licensed pharmacy against a valid prescription — never sold as a supplement or without a prescription.
Clear cancellation and refund terms
You should be able to find the cancellation policy and understand when a charge is or is not refundable before you start.
How Surfbound's oral GLP-1 program works
The facts below describe what Surfbound Health actually provides — separate from what the clinical trials above establish. Lower cost, convenience, or access are not presented here as evidence of clinical superiority.
- Formulations currently offered
- Compounded oral semaglutide, compounded oral tirzepatide, and a compounded oral semaglutide + tirzepatide combination, all taken as daily tablets. All are compounded and not FDA-approved; there is no FDA-approved oral tirzepatide and no FDA-approved combination.
- Current prices
- Compounded oral semaglutide is $259/mo and compounded oral tirzepatide is $319/mo for a 1-month supply. The compounded oral semaglutide + tirzepatide combination is $365/mo for a 1-month supply. Prices are the same at every dose.
- What each program includes
- The monthly price includes the medication if prescribed, the licensed provider review, ongoing dosing support, and discreet shipping. There is no separate membership or consultation fee.
- Monthly vs. prepaid billing
- The 1-month supply is billed monthly and renews until you cancel. There are also 3- and 6-month prepaid supplies: the package total is charged together once your medication is approved, and the full supply ships together as one package.
- How provider evaluations work
- You complete a short online health intake, and an independent licensed provider reviews your history and determines which option, if any, is medically appropriate. Prescription is never automatic.
- If treatment is not approved
- Nothing is charged unless your medication is approved.
What the monthly price includes
- Medication, if a licensed provider prescribes it
- An independent licensed provider review
- Ongoing dosing support
- Discreet shipping to your door
Treatment availability depends on your state, the formulation requested, and clinician licensure, and is confirmed during provider review. You can check availability by state on the locations page, and review dispensing pharmacy information on the pharmacy partners page.
Explore the oral GLP-1 options
See the full oral GLP-1 lineup and pricing, or start a secure intake for a licensed provider review.
Start secure provider reviewPrescription required. Not everyone qualifies. Nothing is charged unless your medication is approved.
References
- 1.OASIS 1 — Knop FK, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, multinational trial. The Lancet, 2023. The Lancet / PubMed · 2023
- 2.OASIS 4 — Oral semaglutide 25 mg in adults with overweight or obesity (OASIS 4): a randomised, double-blind, placebo-controlled trial. Primary efficacy endpoint at 64 weeks. PubMed · 2025
- 3.PIONEER 4 — Pratley R, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. The Lancet, 2019. The Lancet / PubMed · 2019
- 4.Rybelsus (semaglutide) tablets, for oral use — U.S. Prescribing Information. Describes the co-formulation with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) and the required administration instructions. Novo Nordisk — U.S. Prescribing Information · 2024
- 5.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers — compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing. U.S. Food and Drug Administration · 2026
Educational content only; it is not medical advice and does not replace an individual evaluation by a licensed provider. Compounded medications are not FDA-approved. This article is published by Surfbound Health (Organization); it has not been individually physician-reviewed, so no physician-review claim is made here.